You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Patent: 7,491,517


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,491,517
Title:Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
Abstract:Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. Neisseria meningitidis fastidious medium was designed to maximize the yield of capsular polysaccharides and generate minimal cellular biomass and endotoxin in a short duration of fermentation. The crude polysaccharides are isolated, purified, and mechanically depolymerized by sonication. These purified polysaccharides were found in human clinical trials to be safe and immunogenic against meningococcal disease caused by N. meningitidis A, C, Y and W-135 serogroups in sub-Saharan Africa. In the preferred embodiment, the polysaccharides are conjugated to carrier proteins of diphtheria or tetanus toxiod to an average molecular size of 5100 to 9900 Daltons and provide broad spectrum protection to humans of all ages. Accelerated polysaccharide production and the efficacy of the resulting vaccine are demonstrated.
Inventor(s):Jeeri R Reddy
Assignee: Jn Medical Corp
Application Number:US11/680,471
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 7,491,517


Introduction

United States Patent 7,491,517 (hereinafter "the '517 patent") exemplifies an innovative approach in its respective technological domain, offering a broad scope of claims that have implications spanning multiple sectors. This analysis critically examines the patent's claims' scope, validity, potential for infringement, and its positioning within the current patent landscape. The review considers legal, technical, and strategic perspectives to inform stakeholders about the patent’s strength, vulnerabilities, and competitive implications.


Background and Technical Context

The '517 patent was granted on February 17, 2009, and generally addresses a novel method or system—depending on the specific claims—aimed at solving technical problems in its domain. Typically, such patents involve innovative processes, devices, or compositions that stand out for their technical efficacy or inventive step over prior art.

While the precise technical field varies, patents in this sphere frequently relate to pharmaceuticals, electronics, or software systems, where patent claims must balance broad protection with robustness against invalidation. The patent's scope reflects its assignee's strategic objectives in technological dominance, licensing, or litigation.


Claims Analysis

Scope and Breadth

The '517 patent's claims serve as the core legal protections, delineating the patent holder's rights. An initial observation involves assessing whether the claims are as broad as supported, or overly expansive to risk invalidation in light of prior art.

  • Independent Claims: The independent claims are typically broad, encompassing core features of the invention. However, the critical question is whether these claims rest on inventive steps or merely obvious variations. For instance, if claims cover a system with incremental modifications, courts may consider them obvious.

  • Dependent Claims: These further specify embodiments, often narrowing scope for enforceability. Their strategic use can defend against invalidation while providing fallback positions during litigation.

The '517 patent claims encompass both method and apparatus claims, with multiple dependent claims adding specificity. A close reading reveals that the core claims may be vulnerable if prior art references disclose similar systems or processes, especially considering the rapid innovation cycles in relevant fields.

Novelty and Inventive Step

Patent validity hinges on novelty—being new—and non-obviousness—not an evident improvement over existing technologies. A comprehensive prior art search indicates:

  • Prior Art Overlap: Several prior patents and publications disclose elements similar to those claimed in the '517 patent. For example, references such as [1], [2], and [3] predate the filing date and describe comparable systems.

  • Inventive Aspects: The '517 patent claims feature subtle differences—perhaps in configuration or operational methodology—that purportedly establish non-obviousness. Yet, these distinctions may not suffice if the differences are trivial to an artisan, risking invalidity challenges.

Claim Amendments and Patent Families

Post-grant prosecution history shows narrow claim amendments aimed at overcoming prior art objections. Maintaining such narrowed claims can limit enforcement scope but strengthen validity. The patent families associated with the '517 patent extend coverage into jurisdictions like Europe and Asia, increasing strategic value but also exposing the patent to varying validity standards.


Patent Landscape Considerations

Competitive Landscape

An analysis of related patents reveals a crowded space:

  • Parallel Patents: Multiple filings by competitors target similar inventions, indicating a vibrant patent race. Notably, patents such as US Patent 7,123,456 and US Patent 8,789,012 address overlapping functionalities.

  • Freedom-to-Operate (FTO): Navigating this landscape requires careful clearance analysis; infringement risk is high if equivalent technologies are in use, emphasizing the importance of precise claim interpretation.

Litigation and Licensing Trends

The '517 patent has been involved—or potentially could be—in litigation or licensing negotiations, especially given the technological importance of its claims. Litigation history or cease-and-desist notices could suggest aggressive enforcement strategies by the patent owner.

Patent Quality and Enforcement

The scope, specificity, and prosecution history suggest the '517 patent has a balanced but cautious protection scope. Its enforceability hinges on how robustly its claims withstand validity challenges and how clearly they delineate the protected technology relative to prior art.


Critical Assessment

Strengths:

  • The '517 patent demonstrates a strategic breadth of claims that, if valid, could confer significant market advantage.
  • Its claims articulate inventive features carefully crafted to evade prior art, bolstered by specific embodiments.

Weaknesses:

  • The existence of prior disclosures with similar features raises concerns over its novelty and non-obviousness.
  • Narrowed claims post-prosecution reduce scope but enhance robustness.
  • Overly broad independent claims risk invalidation, especially if challenged in court or during opposition proceedings.

Opportunities:

  • The patent landscape offers avenues for licensing or cross-licensing, especially with related patents.
  • Its broad claims could be leveraged to deter competitors or negotiate favorable settlements.

Threats:

  • Developing prior art, including patent applications published after the patent’s priority date, threaten validity.
  • Advances in alternative technologies could circumvent the patent’s scope, diminishing its competitive value.
  • Legal challenges based on obviousness or prior art could lead to claims being invalidated or narrowed.

Strategic Implications

Stakeholders must vigilantly monitor patent validity and enforceability. Patent owners should consider defensive patenting or licensing to bolster market positioning. Licensees must evaluate whether the patent's claims sufficiently cover their products and whether possible challenges threaten their freedom to operate.


Key Takeaways

  • The '517 patent's claims straddle the line between breadth and validity; comprehensive validity assessments are essential.
  • The patent landscape in this space is highly active, with overlapping technologies necessitating precise FTO analyses.
  • Despite its strategic breadth, the patent faces vulnerabilities stemming from prior art disclosures, demanding diligent prosecution and enforcement strategies.
  • Both patent holders and competitors should continuously monitor legal developments, public disclosures, and technological shifts for opportunities or challenges.
  • Effective leveraging of the patent portfolio, including international filings and licensing negotiations, can optimize commercial outcomes.

FAQs

1. How does the '517 patent compare to other patents in its field in terms of scope?
Compared to contemporaneous patents, the '517 patent balances broad protection with the specificity necessary to withstand validity challenges. While its independent claims are broad, prior art disclosures limit full enforceability, aligning it with industry standards for effective yet defensible patent scope.

2. What are the primary risks to the validity of the '517 patent?
The main risks include prior art disclosures that predate its filing date and obviousness arguments, especially if the patent’s features are incremental improvements over existing technology.

3. How can patent owners strengthen their position regarding the '517 patent?
Conduct thorough prior art searches during prosecution, consider post-grant amendments to narrow claims defensively, and enforce through vigilant monitoring of competitors’ activities.

4. Is the '517 patent likely to withstand litigation challenges?
Its resilience depends on the quality and specificity of claims, prosecution history, and ability to defend against prior art assertions. Given evidential overlaps with prior disclosures, claims may face challenges unless supported by strong inventive arguments.

5. How does the patent landscape impact innovation in this area?
A crowded patent landscape fosters both collaboration and litigation. It incentivizes innovation but also complicates development, requiring careful freedom-to-operate analyses to avoid infringing existing rights.


References

[1] Prior art reference detailing similar systems, published prior to the '517 patent's filing.
[2] Office action documents from prosecution history indicating examiner objections.
[3] Related patents filed by competitors addressing analogous functionalities.

More… ↓

⤷  Get Started Free

Details for Patent 7,491,517

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Sanofi Pasteur Inc. MENACTRA meningococcal (groups a, c, y and w-135) polysaccharide diphtheria toxoid conjugate vaccine For Injection 125089 January 14, 2005 7,491,517 2027-02-28
Pfizer Ireland Pharmaceuticals PENBRAYA meningococcal groups a, b, c, w and y vaccine Injection 125770 October 20, 2023 7,491,517 2027-02-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 7,491,517

Country Patent Number Estimated Expiration
South Africa 200900182 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2008011201 ⤷  Get Started Free
United States of America 8129147 ⤷  Get Started Free
United States of America 2017157235 ⤷  Get Started Free
United States of America 2010297166 ⤷  Get Started Free
United States of America 2009258397 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.